A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Janssen Research & Development, LLC Clinical Trial
Janssen Research & Development, LLC
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
187 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Cemic (centro de Educación Médica E Investigaciones Clínicas)
Buenos Aires, Argentina
- Centro Oncológico Korben
Buenos Aires, Argentina
- Iadt Instituto Argentino de Diagnostico Y Tratamiento
CABA, Argentina
- Cemaic Centro Privado de Especialidades Medicas Ambulatorias E Investigacion Clinica
Córdoba, Argentina
- Sanatorio Allende
Córdoba, Argentina
- Clínica Viedma
Viedma, Argentina
- Cancer Research Sa
Adelaide, Australia
- Chris O'Brien Lifehouse
Camperdown, Australia
- Peter Maccallum Cancer Centre
Melbourne, Australia
- St John of God Hospital Murdoch
Murdoch, Australia
- Westmead Hospital
Westmead, Australia
- Princess Alexandra Hospital
Woolloongabba, Australia
- Fundacao Pio Xii
Barretos, Brazil
- Cetus Oncologia
Belo Horizonte, Brazil
- Instituto Cionc de Ensino E Pesquisa S/s
Curitiba, Brazil
- Ynova Pesquisa Clinica
Florianópolis, Brazil
- Fundacao Sao Francisco Xavier Hmc Unidade de Oncologia
Ipatinga, Brazil
- Upco Unidade de Pesquisa Clinica Em Oncologia
Pelotas, Brazil
- Uniao Brasileira de Educacao E Assistencia Hospital Sao Lucas Da Pucrs
Porto Alegre, Brazil
- Impar Servicos Hospitalares S/a
Rio de Janeiro, Brazil
- Instituto D Or de Pesquisa E Ensino Idor
Rio de Janeiro, Brazil
- Oncoclinicas Rio de Janeiro S A
Rio de Janeiro, Brazil
- Nucleo de Oncologia Da Bahia
Salvador, Brazil
- Cepho Centro de Estudos E Pesquisa de Hematologia E Oncologia
Santo André, Brazil
- Impar Servicos Hospitalares Sa Hospital Nove de Julho
São Paulo, Brazil
- Núcleo de Pesquisa São Camilo
São Paulo, Brazil
- Onco Star Sp Oncologia Ltda
São Paulo, Brazil
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
São Paulo, Brazil
- the Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
- Princess Margaret Hospital
Toronto, Ontario, Canada
- Beijing Chest Hospital, Capital Medical University
Beijing, China
- Beijing Friendship Hospital Capital Medical University
Beijing, China
- Beijing Shijitan Hospital, Capital Medical University
Beijing, China
- Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China
- Peking University Third Hospital
Beijing, China
- Jilin Cancer Hospital
Changchun, China
- the First People'S Hospital of Changzhou
Changzhou, China
- Sichuan Cancer Hospital
Chengdu, China
- West China Hospital Sichuan University
Chengdu, China
- Chongqing University Cancer Hospital
Chongqing, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 5 Aug 2022
- Primary completion
- 3 Jan 2024
- Completion
- 30 Jun 2027
- Last update posted
- 6 Jul 2026
- Registered enrollment
- 418
- Registry id
- NCT05388669
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.